{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:15:40Z","timestamp":1792282540905,"version":"4.4.0"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:p> PURPOSE: Detection of micrometastases in the regional tumor-draining lymph nodes is critical for accurate staging and prognosis in melanoma patients. We hypothesized that a multiple-mRNA marker (MM) reverse transcriptase\u2013polymerase chain reaction (RT-PCR) assay would improve the detection of occult metastases in the sentinel node (SN), compared with hematoxylin and eosin (H&amp;E) staining and immunohistochemistry (IHC), and that MM expression is predictive of disease relapse. <\/jats:p><jats:p> PATIENTS AND METHODS: Seventy-two consecutive patients with clinical early-stage melanoma underwent sentinel lymphadenectomy (SLND). Their SNs were serially sectioned and assessed for MAGE-3, MART-1, and tyrosinase mRNA expression by RT-PCR, in parallel with H&amp;E staining and IHC, for melanoma metastases. MM expression in the SNs was correlated with H&amp;E and IHC assay results, standard prognostic factors, and disease-free survival. <\/jats:p><jats:p> RESULTS: In 17 patients with H&amp;E- and\/or IHC-positive SNs, 16 (94%) expressed two or more mRNAmarkers. Twenty (36%) of 55 patients with histopathologically negative SNs expressed two or more mRNA markers. By multivariate analysis, patients at increased risk of metastases to the SN had thicker lesions (P\u2009=\u2009.03), were 60 years of age or younger (P\u2009&lt;\u2009.05), and\/or were MM-positive (P\u2009&lt;\u2009.001). Patients with histopathologically melanoma-free SNs who were MM-positive, compared with those who were positive for one or fewer mRNA markers, were at increased risk of recurrence (P\u2009=\u2009.02). Patients who were MM-positive with histopathologically proven metastases in the SN were at greatest risk of disease relapse (P\u2009=\u2009.01). <\/jats:p><jats:p> CONCLUSION: H&amp;E staining and IHC underestimate the true incidence of melanoma metastases. MM expression in the SN more accurately reflects melanoma micrometastases and is also a more powerful predictor of disease relapse than are H&amp;E staining and IHC alone. <\/jats:p>","DOI":"10.1200\/jco.1999.17.10.3238","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T06:56:34Z","timestamp":1487919394000},"page":"3238-3244","source":"Crossref","is-referenced-by-count":212,"title":["Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase\u2013Polymerase Chain Reaction in Early-Stage Melanoma Patients"],"prefix":"10.1200","volume":"17","author":[{"given":"Peter J.","family":"Bostick","sequence":"first","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Morton","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick R.","family":"Turner","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly T.","family":"Huynh","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Elashoff","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Essner","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave S.B.","family":"Hoon","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, John Wayne Cancer Institute, and the Department of Pathology, Saint John's Health Center, Santa Monica, and the Department of Biomathematics, University of California Los Angeles School of Medicine, Los Angeles, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-3238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2361"},{"key":"R2-3238","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199110000-00013"},{"key":"R3-3238","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78608-6"},{"key":"R4-3238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1430"},{"key":"R5-3238","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1992.01420040034005"},{"key":"R6-3238","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910340204"},{"key":"R7-3238","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.16.1410"},{"key":"R8-3238","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92100-G"},{"key":"R9-3238","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<454::AID-IJC11>3.0.CO;2-A"},{"key":"R10-3238","unstructured":"Kuo  CT,  Bostick  PJ,  Irie  RF, et al: Assessment of messenger RNA of \u03b21 \u2192 4-acetylgalactosaminyltransferase as a molecular marker for metastatic melanoma.  Clin Cancer Res 4:411,1998-418, N"},{"key":"R11-3238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2826"},{"key":"R12-3238","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.9.590"},{"key":"R13-3238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2091"},{"key":"R14-3238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.2109"},{"key":"R15-3238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1751"},{"key":"R16-3238","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3207(18)30610-0"},{"key":"R17-3238","unstructured":"Sarantou  T,  Chi  DD,  Garrison  DA, et al: Melanoma-associated antigens as messenger RNA detection markers for melanoma.  Cancer Res 57:1371,1997-1376,"},{"key":"R18-3238","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2632"},{"key":"R19-3238","unstructured":"Chi  DD,  Merchant  RE,  Rand  R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.  Am J Pathol 150:2143,1997-2152,"},{"key":"R21-3238","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.46.4.225"},{"key":"R22-3238","unstructured":"Livingston  P: Ganglioside vaccines with emphasis on GM2.  Semin Oncol 25:636,1998-645,"},{"key":"R23-3238","doi-asserted-by":"crossref","unstructured":"Ludwig Trial, International Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers.  Lancet 335:1565,1990-1568,","DOI":"10.1016\/0140-6736(90)91386-O"},{"key":"R24-3238","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199609000-00002"},{"key":"R25-3238","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.134.1.43"},{"key":"R26-3238","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1997.01430300108021"},{"key":"R27-3238","doi-asserted-by":"publisher","DOI":"10.1016\/S0748-7983(96)80017-5"},{"key":"R28-3238","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199607000-00006"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.10.3238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:35:46Z","timestamp":1653514546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.10.3238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1200\/JCO.1999.17.10.3238"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.10.3238","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}